ReviewDeutsches Arzteblatt international2026
Central Serous Chorioretinopathy: Etiology, Diagnosis, and Treatment.
Review in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ocular surface disease and psychological distress in central serous chorioretinopathy.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentral serous chorioretinopathy (CSC) is a rare eye disease (estimated prevalence 1.4 per 10 000 people) characterized by a serous fluid collection under the central portion of the retina. Its pathogenesis and optimal treatment remain incompletely understood.
methodsIn this narrative review, we discuss the risk factors, pathophysiology, diagnostic evaluation, and treatment of CSC.
resultsSystemic corticosteroids are considered a well-documented precipitating factor for the disease (odds ratio 4.29, 95% confidence interval [2.01; 9.15]). Potential psychosomatic factors have been inadequately studied. The pathophysiology is likewise incompletely understood; choroidal vascular dysregulation and hyperpermeability appear to be key mechanisms. The resulting fluid collection under the retina can markedly impair photoreceptor function and vision. In 80%-90% of acute cases, the fluid is spontaneously resorbed. Various treatments, ranging from laser therapy to medication-based approaches, have been proposed for patients who do not experience spontaneous remission, but non of them has been found to yield superior functional outcomes in network meta-analyses. Morphologically, in two randomized trials, subretinal fluid regressed in 67% and 78%, respectively, of patients treated with photodynamic therapy, compared to 29% and 17% after micropulse laser treatment or oral eplerenone.
conclusionCSC is still incompletely understood, and the treatment options for it are a matter of debate. There is an urgent need for further controlled prospective trials with an adequate period of observation and functional endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.